[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Women's College Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":454},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,69,109,133,160,185,207,231,255,281,307,327,350,377,401,427],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641869","advancing-online-psychology-tools-for-chronic-pain-100641869",false,"NCT07659873","Advancing Online Psychology Tools for Chronic Pain","Advancing Online Psychology Tools for Chronic Pain (ADOPT-CP): Feasibility of a Scalable Digital Psychology Intervention and AI-Powered Support for Patients on the Waitlist for Pain Services","ADOPT-CP","Inclusion Criteria:\n\n1. Must be deemed to have capacity to provide informed consent;\n2. Must sign and date the informed consent form;\n3. Must state willingness to comply with all study procedures;\n4. Must be at least 18 years of age;\n5. Must be referred to TAPMI;\n6. Must have either fibromyalgia or chronic pelvic pain\n7. Must be on the waitlist at TAPMI;\n8. Must have access to a device that can connect to the Internet with access to email.\n\nExclusion Criteria:\n\n1. Currently engaged in psychotherapy or engaged in psychotherapy within the last month at the time of enrolment;\n2. Unable to read, understand, or communicate in English sufficiently to provide informed consent and complete the study procedures and questionnaires;\n3. Has active serious mental illness or psychiatric instability that, in the opinion of the research team, may impair the ability to safely participate in the study or to provide informed consent (e.g., active psychosis, active mania);\n4. Has a visual, auditory, or other functional impairment that would prevent independent access to and use of the digital intervention and study procedures on an internet-enabled device.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Chronic pain affects more than 20% of Canadians and is associated with significant impacts on physical function, mental health, and quality of life. Despite efforts to improve access to multidisciplinary pain care through centralized referral systems, many patients continue to experience prolonged wait times before receiving treatment.\n\nThis study evaluates a self-guided digital psychological intervention designed to support chronic pain self-management during the waiting period for specialized pain care. The intervention was developed through a collaboration between the Transitional Pain Service and ManagingLife and aims to improve access to evidence-based psychological support, enhance self-management skills, and reduce pain-related distress among individuals living with chronic pain.",[27,28],"Fibromyalgia","Chronic Pelvic Pain Syndrome","NOT_YET_RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":21},"2026-10",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"Women's College Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100617842","single-row-versus-double-row-repair-for-achilles-insertional-tendinopathy-100617842","NCT07323875","Single-Row Versus Double-Row Repair for Achilles Insertional Tendinopathy","Single-Row Versus Double-Row Repair in the Surgical Management of Achilles Insertional Tendinopathy: A Randomized Controlled Trial (STRIDE Trial)","STRIDE","Inclusion Criteria:\n\n1. Must be deemed to have capacity to provide informed consent;\n2. Must sign and date the informed consent form;\n3. Stated willingness to comply with all study procedures;\n4. Adult patients between the ages of 18 and 75 years with symptomatic chronic Achilles insertional tendinopathy for a minimum of 3 months\n5. Failure of non-operative management (which includes physiotherapy, stretching exercises, heel lifts, nonsteroidal anti-inflammatory drugs (NSAIDs), activity modification, etc.) for at least 3 months.\n6. Preoperative imaging (x-ray and Medical Resonance Imaging (MRI)) is available and completed;\n7. Willingness of patients to follow the postoperative rehabilitation protocol;\n8. Willingness of patients to be available for follow up appointments for up to 2 years.\n\nExclusion Criteria:\n\n1. Non-insertional Achilles tendinopathy;\n2. Achilles tendon rupture;\n3. Previous Achilles tendon surgery;\n4. Oral steroid use or steroid injection within 3 months of surgery;\n5. History of connective tissue or collagen disorder (e.g. Marfan Syndrome)\n6. History of chronic inflammatory disorders\n7. History of neurological disease (stroke, cerebral palsy)\n8. History of using more than 30mg of oxycodone or equivalent per day;\n9. Current cigarette smoker (Former smokers must have quit for minimum of one year)\n10. Diabetes type I or II\n11. Pregnancy\n12. Hypersensitivity to metal, Polylactic Acid (PLA), or Polyetheretherketone (PEEK) materials\n13. Active infection\n14. Worker's compensation claim (e.g. WSIB)\n15. History of cognitive or mental health conditions that would make the participant unable to complete study procedures\n16. Non-English speaking","75 Years",{"count":52,"type":21},166,[24],"Achilles insertional tendinopathy may require surgical debridement and tendon reattachment when non-operative treatment fails. Single-row and double-row repairs are used, with biomechanical studies favoring double-row, but clinical evidence of improved outcomes is lacking and costs are higher. This multi-center randomized trial will use the VISA-A score to compare outcomes and inform cost-effective, evidence-based surgical care.",[56,57],"Achilles Insertional Tendinopathy","Achilles Tendinopathy",[59,60,61],"single row repair","double row repair","calcaneal insertion",{"date":63,"type":33},"2026-06-17",{"date":65,"type":21},"2026-09",{"date":67,"type":21},"2030-03",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":90,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":41},"100587602","judicious-surveillance-for-trastuzumab-induced-cardiotoxicity-in-the-first-year-100587602","NCT06930521","JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year","JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year (JUSTIFY): a Randomized Controlled Trial","JUSTIFY","Inclusion Criteria:\n\n1. Stage 1-3 breast cancer (BC).\n2. Age 18-79 years.\n3. HER-2 positive BC with planned HER2 targeted therapy (HER2TT) for curative intent.\n\nExclusion Criteria:\n\n1. Distant metastases detected clinically, radiographically, or histologically\n2. Baseline echocardiogram images of insufficient quality for a quantitative assessment of left ventricular ejection fraction (LVEF)\n3. Pre-existing cardiovascular disease, defined as:\n\n   1. Prior myocardial infarction (even if LVEF has normalized)\n   2. Prior heart failure (HF, including patients with preserved ejection fraction and normalized LVEF)\n   3. Baseline LVEF \\\u003C55%\n   4. Atrial fibrillation\n   5. Greater than moderate valvular disease (i.e., severe, or moderate-severe)\n4. Cumulative anthracycline exposure ≥250mg\u002Fm2 before starting HER2TT\n5. New York Heart Association Functional Class II, III or IV, or Eastern Cooperative Oncology Group score \\>2\\*\n6. Symptoms potentially due to serious cardiac disease as per investigator's judgement\\* \\*Exclusion criterion adopted as they make clinical assessment less reliable to detect emergent HF.","79 Years",{"count":79,"type":21},300,[24],"This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor. The problem is that these treatments, while effective for the cancer, can sometimes harm the heart. Because of this, patients have to undergo heart tests every three months during treatment, even if they have no history of heart disease or feel fine.\n\nThe guidelines for these regular heart tests were established decades ago when these treatments were first introduced, but research shows that most of these tests don't actually change the treatment plan. This suggests that many patients are going through unnecessary tests, which can cause stress, delay treatments, and increase healthcare costs.\n\nTo address this, the researchers propose a new study with 300 patients with HER2 positive breast cancer to test a more personalized approach to cardiac surveillance. Participants will be classified based on their risk of heart problems: low or intermediate. Instead of testing every patient every three months, those in the intermediate group will be tested every 4 months, and those in the low-risk group will be tested every 6 months. The researchers will compare this new approach to the current system to see if fewer tests are just as safe and effective.\n\nThe researchers will measure heart health, how well cancer treatments are completed, and how patients feel about having fewer tests. If this new approach works, it could save money and reduce the burden on female patients without risking their health.",[83,84,85,86,87,88,89],"Cardiovascular Health","Breast Cancer","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Cardio-oncology","Circulatory and Respiratory Health","Clinical and Translational Cardiovascular Sciences","Health Services and Systems - Healthcare Effectiveness &Amp; Outcomes",[91,92,93,94,95,96,97,98,99,100],"Trastuzumab","Cardiac imaging","Her-2 positive breast cancer","Echocardiography","Cardiotoxicity","Left ventricular ejection fraction","Heart failure","Randomized controlled trial","Nuclear imaging","Non-inferiority","RECRUITING","2026-06-11",{"date":30,"type":33},{"date":105,"type":33},"2026-04-22",{"date":107,"type":21},"2033-06",{"name":39,"class":40},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100581594","evaluating-the-eapoc-copd-system-100581594","NCT06852339","Evaluating the EAPOC-COPD System","Bringing Evidence to the Point-of-Care in Chronic Obstructive Pulmonary Disease: The EAPOC-COPD System","EAPOC-COPD","The study will involve two groups of participants: pharmacy team members and adult patients with COPD who interact with the EAPOC-COPD system during pharmacy encounters.\n\nPharmacy team participants will include pharmacists, registered pharmacy technicians, pharmacy assistants, and students working at one of the six participating community pharmacies. Individuals will be eligible if they are employed at one of the participating sites, have used the EAPOC-COPD system during the study period, are able to provide informed consent, and are able to complete an electronic questionnaire in English. Individuals will be excluded if they have not used the system during the study period or decline to participate.\n\nPatient participants will include adults aged 18 years or older who interact with the EAPOC-COPD system during routine pharmacy care. Eligible patients will be those identified by pharmacy staff as receiving COPD-related care and who complete the EAPOC-COPD patient questionnaire during their pharmacy encounter. Patients must have also indicated willingness to be contacted regarding research participation and be able to provide informed consent. Patients who are under 18 years of age, otherwise unable to provide informed consent, or who decline participation will be excluded.",{"count":118,"type":21},25,[24],"This study evaluates the implementation and impact of the Evidence-at-the-Point-of-Care Chronic Obstructive Pulmonary Disease (EAPOC-COPD) system, a computerized clinical decision support system designed to improve the quality of COPD care delivered in community pharmacies. Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and healthcare utilization, and significant gaps persist in key evidence-based practices, including symptom and exacerbation risk assessment, appropriate pharmacotherapy, provision of COPD action plans, and referral for specialist care.\n\nThe EAPOC-COPD system builds on a previously validated asthma platform and provides pharmacists with guideline-based decision support through a structured patient questionnaire and point-of-care recommendations, including treatment optimization and generation of personalized action plans.\n\nThis study will be conducted across six community pharmacies implementing the EAPOC-COPD system as part of a quality improvement initiative. Using a quasi-experimental interrupted time series design, outcomes during a 12-month intervention period will be compared to a 12-month pre-intervention baseline period.\n\nThe study will evaluate both implementation outcomes (including system uptake, usability, feasibility, and acceptability among pharmacy teams and patients) and effectiveness outcomes. Effectiveness outcomes include improvements in guideline-based COPD care processes, such as rates of symptom and exacerbation risk assessment, optimization of pharmacotherapy, provision of COPD action plans, and appropriate referral for specialist care.\n\nResults from this study will inform the scalability and broader implementation of pharmacy-based clinical decision support tools to enhance chronic disease management and support the expanding role of pharmacists in delivering evidence-based COPD care.",[122],"COPD",[122,124],"clinical decision support","2026-05-12",{"date":127,"type":33},"2026-05-18",{"date":129,"type":21},"2026-07-01",{"date":131,"type":21},"2028-09-01",{"name":39,"class":40},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":140,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":41},"100615626","phase-4-3-ml-inhaled-methoxyflurane-for-intrauterine-device-iud-insertion-100615626","NCT07295054","3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion","A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion","Inclusion Criteria:\n\n1. Patients with a uterus.\n2. Ages 18 to 55 years.\n3. Undergoing any intrauterine device (IUD) insertion.\n4. English-speaking participants.\n5. Ability to use an inhaler device.\n6. Willing to receive a cervical block for their IUD insertion\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. Confirmed pregnancy.\n3. Use of pain medication other than NSAIDs or acetaminophen (e.g., opioids, benzodiazepines, muscle relaxants) within 24 hours prior to the intervention.\n4. Use of cannabis within 24 hours prior to the intervention.\n5. Administration of misoprostol within 24 hours prior to the intervention.\n6. Altered level of consciousness due to any cause, including head injury, drugs, or alcohol.\n7. History of severe adverse reactions to Penthrox (methoxyflurane) or other halogenated anesthetic agents, or to any ingredient in the formulation (including non-medicinal ingredients or container components).\n8. Anatomical variance, such as distorted uterine cavity, bicornuate uterus, uterus didelphys, or cervical stenosis.\n9. Clinically significant renal and\u002For liver impairment.\n10. Known or genetic susceptibility to malignant hyperthermia.\n11. Clinically evident hemodynamic or cardiovascular instability, or respiratory depression.\n12. Not NPO according to hospital guidelines.","FEMALE","55 Years",{"count":143,"type":21},110,[145],"PHASE4","Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.",[148],"IUD",[150,151],"Methoxyflurane","Penthrox","2026-05-07",{"date":154,"type":33},"2026-05-11",{"date":156,"type":33},"2026-04-27",{"date":158,"type":21},"2027-02",{"name":39,"class":40},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":184,"locationsCount":41},"100584244","popliteal-nerve-block-for-acute-achilles-tendon-rupture-repair-surgery-100584244","NCT06886815","Popliteal Nerve Block for Acute Achilles Tendon Rupture Repair Surgery","The Effects of Popliteal Nerve Block on Pain and Nerve-Related Symptoms After Acute Achilles Tendon Rupture Repair Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 - 65\n* ASA classification: I - III\n* BMI \\\u003C 35 kg\u002Fm2\n* Undergoing acute Achilles tendon rupture repair surgery as a day surgery procedure\n\nExclusion Criteria:\n\n* Pre-existing neurological deficits or peripheral neuropathy in the distribution of the tibial or common peroneal nerves\n* Local infection\n* Contraindication to regional anesthesia (e.g., bleeding diathesis, coagulopathy)\n* History of use of over 30 mg oxycodone or equivalent per day\n* Contraindication to any component of a standard multi-modal analgesia\n* Allergy to local anesthetics\n* History of significant psychiatric conditions that may affect patient assessment\n* Pregnancy\n* Inability to provide informed consent\n* Patient refusal of popliteal nerve blockade\n* Prior Achilles tendon surgeries on the operative leg\n* Unable to speak or read English","65 Years",{"count":169,"type":21},80,[24],"Achilles tendon rupture is common, yet the value of popliteal nerve block for postoperative pain control during surgical repair remains uncertain. Despite widespread use, evidence supporting its analgesic effectiveness is limited, and both popliteal nerve block and Achilles tendon repair carry risks of nerve injury. This randomized, placebo-controlled trial will evaluate whether adding a popliteal nerve block to standard systemic analgesia improves postoperative pain and reduces opioid use in patients undergoing acute Achilles tendon rupture repair. Secondary outcomes will examine the incidence and impact of nerve complications on recovery, including return to physical activity and functional performance.",[173],"Acute Achilles Tendon Rupture",[175,176,177],"Popliteal Nerve Block","Lower Extremity Regional Anesthesia","Achilles Tendon","2026-04-21",{"date":180,"type":33},"2026-04-23",{"date":182,"type":33},"2026-03-17",{"date":37,"type":21},{"name":39,"class":40},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100385667","fab-block-vs-placebo-for-hip-arthroplasty-patients-100385667","NCT04301687","FAB Block vs. Placebo for Hip Arthroplasty Patients","The Analgesic Efficacy of the Ultrasound-Guided Femoral Articular Branch Block for Ambulatory Hip Arthroplasty: A Randomized-Controlled Trial Secondary IDs:","Inclusion Criteria:\n\n* ASA I-III patients\n* Ages 18-60yrs\n* BMI ≤ 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Preexisting neurological deficits or peripheral neuropathy in the distribution of femoral, obturator, or lateral cutaneous nerves\n* Local infection\n* Contra-indication to regional anesthesia e.g. bleeding diathesis, coagulopathy\n* Chronic pain disorders\n* History of use of over 30mg oxycodone or equivalent per day\n* Contraindication to a component of multi-modal analgesia\n* Allergy to local anesthetics\n* History of significant psychiatric conditions that may affect patient assessment\n* Pregnancy\n* Inability to provide informed consent\n* Patient refusal of FAB\n* Revision arthroscopy surgeries","85 Years",{"count":194,"type":21},95,[24],"Hip arthroplasty surgery can be associated with significant pain. A regional anesthesia technique, the femoral articular branch block (FAB), has recently been proposed to collectively block terminal femoral and accessory obturator nerve branches to the hip joint with a single injection, theoretically blocking most of the innervation relevant to hip arthroscopy while sparing the main femoral nerve branches to the quadriceps muscles. The investigators aim to demonstrate the analgesic benefits of FAB. The investigators hypothesize that FAB will reduce opioid consumption and improve postoperative quality of recovery in patients having hip arthroplasty. This is a randomized, controlled, double-blind study and half the patients will be randomized to receive the femoral articular branch block and the other half of patients will be randomized to receive a placebo block. A comparison of pain will be made between both groups.",[198,199,200],"Hip Arthroplasty","Anesthesia, Regional","Femoral Articular Branch Block",{"date":156,"type":33},{"date":203,"type":21},"2026-12",{"date":205,"type":21},"2028-12",{"name":39,"class":40},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":41},"100619973","knee-arthroplasty-recovery-with-transcranial-direct-current-stimulation-100619973","NCT07351578","Knee Arthroplasty Recovery With Transcranial Direct Current Stimulation","Knee Arthroplasty Recovery With Transcranial Direct Current Stimulation: A Randomized Controlled Pilot Trial","KART","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. American Society of Anesthesiologists (ASA) Physical Classification Status I-III.\n3. Scheduled to undergo unilateral elective primary total knee arthroplasty for advanced osteoarthritis of the knee.\n4. Access to a device running iOS Version 10.0 or above, or Android Version 5.0 or above that can connect to the internet.\n\nExclusion Criteria:\n\n1. History of brain surgery, central nervous system tumors, seizures (including epilepsy), stroke or intracranial implants (e.g plates, screws, deep brain stimulators)\n2. Have vascular, traumatic, infectious, or metabolic lesions or diseases of the brain\n3. Active diagnosis of a sleep disorder, defined as a documented diagnosis of any of the following conditions within the past 12 months, based on patient history or medical record review:\n\n   * Insomnia disorder (e.g., difficulty initiating or maintaining sleep, early morning awakening)\n   * Obstructive sleep apnea (OSA)\n   * Central sleep apnea\n   * Narcolepsy\n   * Restless legs syndrome\n   * REM sleep behavior disorder\n   * Circadian rhythm sleep-wake disorders\n   * Parasomnias (e.g., sleepwalking, night terrors)\n4. Active diagnosis of alcohol use disorder, defined as meeting DSM-5 criteria or documented in the patient's medical record within the past 12 months.\n5. Patients taking opioid medications with a daily Oral Morphine Equivalent (OME) of ≥ 80 mg\n6. Current use of medications or substances known to alter cortical excitability or possess psychoactive properties (e.g., antiepileptics, benzodiazepines, antidepressants, antipsychotics, hallucinogens, dissociatives), as determined by review of the patient's medication list, chart review, and patient history. This includes prescribed medications and illicit substances used within the past 30 days.\n7. Have metallic implants or objects in or on the head, including mouth (e.g. electrodes, stents, clips, pins, braces, shrapnel, jewellery (unremovable)\n8. Use passive or active implanted medical devices (e.g., pacemakers, defibrillators, cochlear implants, natural implants or active body-worn medical devices (e.g., neural stimulation or medication infusion devices)\n9. Have defects in the neurocranium (e.g., post-skull trepanation)\n10. Have large vessel occlusions (e.g., complete blockage of the internal carotid artery or other conditions affecting brain perfusion\n11. Have skin diseases of the scalp\n12. Are using other brain stimulation devices concurrently\n13. Are pregnant\n14. Are unable to provide informed consent\n15. Are unable to wear or tolerate the study device\n16. Unable to speak or read English, or understand device operation instructions",{"count":216,"type":21},70,[24],"Total knee arthroplasty (TKA) is widely performed to reduce pain from advanced osteoarthritis, yet many patients experience severe postoperative pain and up to 25-44% develop chronic postsurgical pain (CPSP). Transcranial direct current stimulation (tDCS), a non-invasive neuromodulation technique, has shown promise in reducing pain and opioid use in early studies but has not been evaluated using comprehensive perioperative, home-based protocols. This study will test whether a home-based tDCS intervention delivered before and after TKA can improve acute pain management and reduce the development of CPSP.",[220,221,222],"Knee Arthroplasty","Transcranial Direct Current Stimulation","Pain, Postoperative","2026-01-09",{"date":225,"type":33},"2026-01-20",{"date":227,"type":21},"2026-05",{"date":229,"type":21},"2027-12",{"name":39,"class":40},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":253,"locationsCount":254},"100613086","phase-3-sustained-mood-improvement-with-laughing-gas-exposure-100613086","NCT07262008","Sustained Mood Improvement With Laughing Gas Exposure","Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Double-Blind Trial","SMILE","Inclusion Criteria:\n\n1. 18 to 65 years of age\n2. Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for Major Depressive Disorder (MDD)\n3. Current major depressive episode as confirmed by the Mini International Neuropsychiatric Interview (MINI) for DSM-5\n4. Experiencing moderate to severe depressive episodes, as defined by the Montgomery-Åsberg Depression Rating Scale (MADRS) \\> 21\n5. Failure of two trials of antidepressant therapy of adequate dose and duration, during the current depressive episode\n6. For women of childbearing potential, use of highly effective or double-barrier methods of contraception. Abstinence is acceptable if it is the preferred and usual lifestyle of the female participant\n7. Capacity to provide informed consent.\n\nExclusion Criteria:\n\n1. Acute suicidality defined as score \\> 4 on MADRS item 10\n2. Diagnosis of Bipolar Disorder\n3. Current substance abuse or dependence and\u002For history of alcohol abuse or dependence within the past year\n4. Dementia\n5. Current or lifetime history of schizophrenia or schizoaffective disorder\n6. Known history of hypersensitivity or allergy to nitrous oxide, midazolam or any ingredients in the study formulations\n7. Contraindication to receiving nitrous oxide (e.g. any condition where air is entrapped within a body and its expansion might be dangerous such as, pneumothorax, elevated intracranial pressure, air embolism, recent middle ear, vitreoretinal or bowel obstruction surgeries, etc.)\n8. Known chronic cobalamin or folate deficiency (e.g. signs of anemia or neurological symptoms, with plasma levels of homocysteine over 15 µmol\u002FL and abnormal red blood cells and leukocytes on a complete blood count CBC) or current methotrexate use\n9. Contraindication to receiving the placebo midazolam (e.g. shock, chronic heart failure, chronic obstructive pulmonary disease, closed-angle glaucoma, renal failure, patients with limited pulmonary reserve or those with severe decline of vital signs)\n10. Daily use of centrally acting medicinal products, such as opioid agonists, (e.g. naloxone and naltrexone) morphine derivatives (e.g. oxycodone, hydrocodone, oxymorphone, codeine), benzodiazepines (e.g. diazepam, clonazepam, alprazolam) and\u002For other central nervous system depressants such as barbiturates (e.g. phenobarbital, pentobarbital, amobarbital) and alcohol within the past week.\n11. Pregnancy or breastfeeding\n12. Received electroconvulsive therapy within the past six months\n13. Received ketamine treatment within the past six months\n14. Received repetitive transcranial magnetic stimulation within the past six months\n15. Unwilling to maintain current antidepressant regimen.",{"count":240,"type":21},120,[242],"PHASE3","Multi-centre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of nitrous oxide on reducing symptoms of depression in patients with treatment resistant depression.",[245,246],"Major Depressive Disorder","Treatment Resistant Depression","2025-12-03",{"date":249,"type":33},"2025-12-10",{"date":251,"type":21},"2026-02-01",{"date":131,"type":21},{"name":39,"class":40},5,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":140,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":280},"100598064","the-pregnancy-and-postpartum-mental-health-optimization-virtual-intervention-network-100598064","NCT07066631","The Pregnancy and Postpartum Mental Health Optimization Virtual Intervention Network","The Pregnancy and Postpartum Mental Health Optimization Virtual Intervention Network (MOVIN): Randomized Controlled Trial","MOVIN","Inclusion Criteria:\n\n1. Adult (age 18 years or older)\n2. Pregnant or postpartum and living with their infant 0-6 months old. This includes all individuals who identify as women, as well as those of female sex who do not identify as women (e.g., non-binary, trans) who are the primary parent for their infant. This includes via natural birth, adoption, or surrogacy.\n3. EPDS score \\>10 at eligibility screening.\n\nExclusion Criteria:\n\n1. Active alcohol or substance use disorder, mania or psychotic disorder (as these conditions are better managed in direct specialty care).\n2. Active suicide plan or intent (as emergent hospital-based care is likely required),\n3. Plan to move out of Ontario during the study.\n4. Unable to complete relevant study procedures and measures online. For the few participants without access to devices\u002Fhome internet, we will budget for tablets\u002Fdata plans.\n5. Unable to complete study activities in English. Note that Google translate is available for the intervention platform and language lines are available for participants so that they can be served in their language of choice, however we are unable to provide translations of all study assessment and questionnaire materials that participants will need to complete during the study.\n6. No primary care clinician (required for collaborative mental health care delivery model).\n7. Currently enrolled in a collaborative mental health care model.",{"count":264,"type":21},570,[24],"Depression, anxiety, and related disorders such as post-traumatic stress and obsessive compulsive disorder affect about 20% of pregnant and postpartum people. When not treated properly, these issues negatively impact not only affected people, but also their children's health and development. Only 1 in 5 receive adequate treatment, so identifying new system-wide approaches to reliably deliver recommended care to perinatal mental health patients all is a crucial health care priority. The Pregnancy and Postpartum Mental health Optimization Virtual Intervention Network (MOVIN) is a scalable perinatal mental health platform building on the evidence-based Collaborative care delivery model. MOVIN's online platform allows patients to connect with a care coordinator to co-develop personalized treatment recommendations, in collaboration with their primary care clinician and a perinatal psychiatrist when needed; progress is tracked to re-evaluate.",[268,269,270,271],"Depression","Postpartum","Anxiety","Pregnancy","2025-11-18",{"date":274,"type":33},"2025-11-24",{"date":276,"type":33},"2025-10-29",{"date":278,"type":21},"2029-03-31",{"name":39,"class":40},2,{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":288,"minAge":18,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":305,"leadSponsor":306,"locationsCount":41},"100558822","saddle-block-with-it-morphine-for-penile-inversion-vaginoplasty-100558822","NCT06556121","Saddle Block With IT Morphine for Penile Inversion Vaginoplasty","The Addition of a Saddle Block With Intrathecal Morphine for Analgesia in Transgender Patients Undergoing Penile Inversion Vaginoplasty: A Randomized Double-blind Placebo-controlled Trial","Inclusion Criteria:\n\n* ASA I-III patients\n* Ages 18-70 years\n* Penile Inversion Vaginoplasty\n\nExclusion Criteria:\n\n* Local infection\n* History of use of over 30mg oxycodone or equivalent per day.\n* Contraindication to a component of multi-modal analgesia\n* Complications or adverse events unrelated to the local anesthetic that precludes evaluation of the primary and secondary outcome measures.\n* Unable to speak or read English.\n* Revision and Vulvaplasty surgeries","MALE","70 Years",{"count":291,"type":21},40,[24],"Penile Inversion Vaginoplasty (PIV) is a transition-related surgery (TRS) that is associated with severe postoperative pain. The optimal pain management strategies for this surgery remain unknown. We hypothesized that the addition of a saddle block with intrathecal morphine would yield clinically important analgesic benefits.",[222],[296,297,298,299,300],"Saddle block","transition","pudendal nerve block","gender confirmation surgery","penile inversion Vaginoplasty","2025-08-07",{"date":303,"type":33},"2025-08-13",{"date":301,"type":33},{"date":203,"type":21},{"name":39,"class":40},{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":4},"100424595","lia-vs-lia--acb-ipack-block-for-total-knee-arthroplasty-100424595","NCT04808947","LIA vs. LIA + ACB-iPACK Block for Total Knee Arthroplasty","The Ideal Analgesic Technique for Total Knee Arthroplasty: A Randomized Comparison Between Local Infiltration Analgesia Alone or Combined With Adductor Canal and iPACK Blocks","Inclusion Criteria:\n\n1. ASA classification I-III\n2. BMI \\\u003C 35 kg\u002Fm2\n3. Having elective unilateral total knee arthroplasty\n\nExclusion Criteria:\n\n1. Bilateral knee surgery.\n2. Pre-existing neurological deficit or peripheral neuropathy in the lower the lower limbs\n3. Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases\n4. Severe, poorly controlled respiratory conditions (severe COPD, severe interstitial lung disease, severe \u002F poorly controlled asthma)\n5. Contraindication to regional anesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)\n6. Patient refusal\n7. Chronic pain disorder\n8. Chronic opioid use (≥30 mg oxycodone \u002F day)\n9. Contraindication (or allergy) to a component of multi-modal analgesia protocol\n10. Allergy to amide local anesthetics used in nerve blocks\n11. Contraindications to spinal anesthesia\n12. Significant psychiatric disorder that would preclude objective study assessment\n13. Pregnancy\n14. Inability to provide informed consent",{"count":20,"type":21},[24],"LIA is the mainstay of postoperative analgesia in patients having knee arthroplasty. The combination of ACB-iPACK blocks has also been proposed as an effective analgesic modality for total knee arthroplasty. However, whether combining these two modalities yields any important incremental analgesic benefit remains unclear. The investigators hypothesized that the addition of ACB and iPACK blocks to LIA will yield clinically important analgesic benefits compared to LIA alone in patients having total knee arthroplasty.",[318,319],"Nerve Block","Neuromuscular Blockade","2025-07-14",{"date":322,"type":33},"2025-07-16",{"date":324,"type":21},"2027-01",{"date":205,"type":21},{"name":39,"class":40},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":41},"100360872","erector-spinae-block-vs-placebo-block-study-100360872","NCT03978780","Erector Spinae Block vs. Placebo Block Study","Quality of Recovery Scores Following Erector Spinae Block vs. Sham Block in Ambulatory Breast Cancer Surgery: A Randomised Controlled Trial","Inclusion Criteria:\n\n* ASA classification: I-III\n* BMI \\\u003C 35 kg\u002Fm2\n* Day surgery procedure\n\nExclusion Criteria:\n\n* Prior ipsilateral breast surgery, excluding lumpectomy\n* Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest\n* Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases\n* Severe, poorly controlled respiratory conditions (severe COPD, severe interstitial lung disease, severe \u002F poorly controlled asthma)\n* Contraindication to regional anaesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)\n* Patient refusal\n* Chronic pain disorder\n* Chronic opioid use (≥30 mg oxycodone \u002F day)\n* Contraindication (or allergy) to a component of multi-modal analgesia protocol\n* Allergy to amide local anaesthetics used in nerve blocks\n* Contraindications to any of the components of the standardized general anaesthesia\n* Significant psychiatric disorder that would preclude objective study assessment\n* Pregnancy\u002F women with nursing infants\n* Unable to provide informed consent\n* Unable to speak and read English",{"count":20,"type":21},[24],"Regional anaesthesia combined with general anaesthesia has become common in the perioperative management of breast cancer surgery patients. Regional techniques have been recognised to provide excellent post-operative analgesia. It enhances multi-modal analgesia regimes while being opioid sparing, reducing incidence of post-operative nausea and vomiting and allowing earlier mobilisation\u002Fdischarge and improving treatment success. Therefore identifying the correct regional anaesthetic technique for this group of patients is important in providing optimum peri-operative care.",[84,318,338,319],"Regional Anesthesia",[340,341,342,343],"Spinae fascial plane block","Breast surgery","interfascial plane block","erector spinae block",{"date":322,"type":33},{"date":346,"type":21},"2026-06",{"date":348,"type":21},"2028-01",{"name":39,"class":40},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":17,"minAge":357,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":362,"conditions":363,"keywords":365,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":41},"100595084","my-lung-health-coach-a-virtual-copd-self-management-support-program-integrated-into-the-electronic-patient-record-100595084","NCT07027852","My Lung Health Coach-A Virtual COPD Self-management Support Program Integrated Into the Electronic Patient Record","MLHC","Inclusion Criteria:\n\n1. Must be deemed to have capacity to provide informed consent;\n2. Must sign and date the informed consent form;\n3. Stated willingness to comply with all study procedures;\n4. Be diagnosed with COPD as per a WCH Respirologist\n5. Be 40 years or older\n6. Be a current or ex-smoker\n7. Preferred but not required: have a history of at least 1 COPD exacerbation (requiring prednisone or antibiotic use, or an urgent healthcare visit of any kind) in the previous 12 months\n\nExclusion Criteria:\n\n1. Experienced a COPD exacerbation in the 4 previous weeks to study enrollment\n2. Co-diagnosis of asthma by a WCH Respirologist\n3. Significant co-morbidities that could interfere with program participation or terminal illness\n4. Unwilling to download and use the Epic Care Companion app and has a unsuitable mobile device to do this\n5. Pregnancy","40 Years","100 Years",{"count":360,"type":21},50,[24],"Study Description: My Lung Health Coach (MLHC) is a virtual COPD education and self-management support program delivered through one-on-one sessions with a Certified Respiratory Educator (CRE) over 12 weeks. It includes six sessions that cover essential COPD topics such as: Basic COPD knowledge, Smoking cessation, Medications (inhalers, oxygen), Physical activity, Mental health and wellness, Vaccinations, Symptom self-management, Nutrition, Travel, and Long-term planning (including end-of-life care). The investigators have also developed a companion app to MLHC integrated into the electronic patient record that patients can access through their EPIC MyHealth app on the participants phones, tablets, or desktops. This study will evaluate the feasibility and effectiveness of MLHC and the companion app.",[364],"Copd",[122,366,367,368],"Telehealth","Telemonitoring","Respiratory","2025-06-16",{"date":371,"type":33},"2025-06-19",{"date":373,"type":33},"2025-01-15",{"date":375,"type":21},"2026-06-05",{"name":39,"class":40},{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":140,"minAge":18,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":280},"100446757","rct-of-at-home-tdcs-for-depression-in-pregnancy-100446757","NCT05097586","RCT of At-Home tDCS for Depression in Pregnancy","Randomized Controlled Trial of At-home Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy","Inclusion criteria:\n\n1. Adult, ≥18 years of age\n2. Singleton pregnancy, 12 to end of 32 weeks single gestation at randomization\n3. In a major depressive episode (MDE) with at least moderate symptom severity (PHQ-9 ≥10 and confirmed using MINI International Neuropsychiatric Interview as MDE without psychotic features)\n4. Assessed by a psychiatrist at one of the study recruitment sites during pregnancy, and offered the option of antidepressant medication for treatment but declined to use\n5. No new treatments for depression (i.e. psychological or somatic) and no pharmacological treatment for depression in the 4 weeks prior to starting treatment\n\nExclusion criteria:\n\n1. Active alcohol or substance use disorder in previous 12 months as assessed by GAIN-SS\n2. Active suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n3. Bipolar disorder as assessed by MINI International Neuropsychiatric Interview\n4. Schizophrenia or other psychotic disorder as assessed by MINI International Neuropsychiatric Interview\n5. Major unstable or life-threatening medical illness (e.g. such as advanced cancer), pre-eclampsia\u002Feclampsia in current pregnancy or neurologic illness or seizure history\n6. Major congenital anomalies or major obstetrical complications in current pregnancy (determined by clinical PI\u002FCo-I assessment)\n7. Metal implants in cranium or any electrical implants\n8. Benzodiazepine (except intermittent low-dose lorazepam no more than 2mg equivalent per day) or anticonvulsant use as these interfere with anodal tDCS\n9. Visibly non-intact skin\u002Frash on scalp areas at stimulation electrode sites\n10. Unable to consent or complete study measures in English, or unable to complete depression in pregnancy workbook (the attention-control) in French or English",{"count":385,"type":21},156,[24],"This is a randomized, sham-controlled trial to determine whether treatment with transcranial direct current stimulation (tDCS) is superior to a sham condition at reducing the symptoms of depression in pregnant people with moderate to severe depression. The study aims to enrol 156 participants across all sites. Data collection occurs at baseline, immediately after treatment, every 4 weeks during pregnancy and 4-, 12-, 26- and 52-weeks postpartum",[389,271,390],"Major Depression","Postpartum Depression",[271,268,392],"Transcranial direct current stimulation","2025-05-21",{"date":395,"type":33},"2025-05-28",{"date":397,"type":33},"2021-11-08",{"date":399,"type":21},"2027-06",{"name":39,"class":40},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":426},"100512705","phase-3-nicotinamide-chemoprevention-for-keratinocyte-carcinoma-in-solid-organ-transplant-recipients---pivotal-trial-100512705","NCT05955924","Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial","Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: a Multicentre, Pragmatic Randomized Trial","SPRINTR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Kidney, liver, heart, or lung transplant at least two years ago\n* History of at least one prior histologically-confirmed keratinocyte carcinoma or squamous cell carcinoma in situ\n* Currently immunosuppressed with a calcineurin inhibitor-based regimen (cyclosporine or tacrolimus)\n* Able to attend follow-up visits\n\nExclusion Criteria:\n\n* Use of nicotinamide or niacin (≥250 mg daily) within past 12 weeks\n* Untreated localized skin cancer at baseline (patient can enrol after skin cancer treatment)\n* Biopsy-confirmed acute rejection episode within the past 12 weeks\n* Active liver disease (high AST \\>3 times or bilirubin \\>1.5 times)\n* Severe kidney disease (estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73 m2)\n* Solid organ or hematologic malignancy, invasive melanoma, Merkel cell carcinoma, or metastatic skin cancer within the past five years\n* Pregnancy or lactation\n* Need for ongoing carbamazepine or primidone\n* Allergy to nicotinamide or any ingredient of the vitamin or placebo capsules",{"count":410,"type":21},396,[242],"As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical.\n\nNicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.",[414,415,416,417],"Non-melanoma Skin Cancer","Carcinoma, Squamous Cell","Carcinoma, Basal Cell","Keratinocyte Carcinoma","2025-02-20",{"date":420,"type":33},"2025-02-21",{"date":422,"type":33},"2023-08-28",{"date":424,"type":21},"2027-08",{"name":39,"class":40},7,{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":437,"phases":4,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":41},"100512585","sex-and-gender-based-analysis-of-the-effectiveness-of-advanced-therapies-in-psoriatic-arthritis-100512585","NCT05954364","Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis","Sex Matters: Sex- And Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis (SAGE-PsA) - an International Multicentre Study","SAGE-PsA","Inclusion Criteria:\n\n* Rheumatologist confirmed diagnosis of PsA according to CASPAR criteria\n* Age ≥18 years\n* Active PsA with any of the following manifestations detected on physical examination: peripheral arthritis, dactylitis, and enthesitis. The patient may have axial involvement in addition to the peripheral manifestations of PsA\n* Plan to start treatment with advanced therapies for peripheral musculoskeletal manifestations of PsA\n\nExclusion Criteria:\n\n* Unable to read or write\n* Unable to sign informed consent\n* Cannot return for a follow up visit\n* The drug is given for another indication and not for active PsA (e.g. psoriasis, IBD)\n* Pregnant women",{"count":436,"type":21},540,"OBSERVATIONAL","Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis (PsA). The investigators hope to discover biological and socio-cultural mechanisms that explain the differences in treatment response between men and women with PsA.\n\nThe study investigators plan to recruit patients from approximately 30 sites across the world. Men and women with active PsA will be assessed before and after they start advanced therapies and information will be collected about sex- and gender-related factors through questionnaires and physical examination. Physicians will assess the patient response to treatment. The investigators will compare the response to treatment in men and women and assess what biological and socio-cultural factors contribute to differences in treatment response.",[440],"Psoriatic Arthritis",[440,442,443,444,445],"Inflammatory Arthritis","Sex","Gender","Advanced Therapies","2023-07-20",{"date":448,"type":33},"2023-07-24",{"date":450,"type":33},"2023-01-23",{"date":452,"type":21},"2026-12-31",{"name":39,"class":40},""]